"Across AMEA, the biopharma industry is seeing a greater emphasis on local production and supply chain resilience"

Avantor, the leading global provider of life sciences and advanced technology solutions, inaugurated Singapore Manufacturing & Distributing Hub (SMDH) mid this year.

- Hithaishi Bhaskar 

Christophe Couturier,
Executive Vice President,
Asia, Middle East and
Africa (AMEA), Avantor 

The expansion of existing Singapore Hub added new cGMP manufacturing suites, quality control laboratory and inventory management expertise for process ingredients and excipients. The hub’s three state-of-the-art facilities allow the hub to drive innovation and efficiency to address the immediate challenges in Asia, Middle East and Africa (AMEA) biopharma industry while addressing biopharmaceutical, biologic, cell, and gene therapy challenges. In a conversation with BioSpectrum Asia, Christophe Couturier, Executive Vice President, AMEA, Avantor explains how the company bolsters its regional capability to advance therapeutic science by launching the Singapore Manufacturing and Distribution Hub. Edited excerpts;

How is Avantor strategising to strengthen supply chain resilience and competitiveness in the AMEA biomedical sphere? 

With rapid advancements in the biopharmaceuticals space, having robust and agile supply chains are crucial in enabling scientific breakthroughs. This includes timely access to critical raw materials, consumables, instruments, as well as ensuring stringent manufacturing processes and transportation to uphold the highest standards of quality. Bolstering regional supply chains is essential for biopharma and is key to mitigating uncertainties such as geopolitical concerns and natural disasters.